Coumarins: Auspicious cholinesterase and monoamine oxidase inhibitors

Current Topics in Medicinal Chemistry

Volumn 15, Issue 17, 2015, Pages 1673-1682

  Orhan, Ilkay Erdogan ^a   Gulcan, H Ozan ^b  

^a GAZI UNIVERSITY   (Turkey)

^b EASTERN MEDITERRANEAN UNIVERSITY   (Turkey)

Author keywords

Alzheimer s disease; Cholinesterase inhibition; Coumarin; Monoamine oxidase

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ANGELICIN; ANSECULIN; BERGAPTEN; CHOLINESTERASE; COUMARIN; METHOXSALEN; SCOPOLETIN; CHOLINESTERASE INHIBITOR; COUMARIN DERIVATIVE; MONOAMINE OXIDASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; CENTRAL NERVOUS SYSTEM; IC50; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; STRUCTURE ACTIVITY RELATION; THIN LAYER CHROMATOGRAPHY; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME ACTIVE SITE;

CATALYTIC DOMAIN; CHOLINESTERASE INHIBITORS; COMPUTATIONAL BIOLOGY; COUMARINS; MOLECULAR STRUCTURE; MONOAMINE OXIDASE INHIBITORS;

EID: 84931829884     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150427113103     Document Type: Article

References (108)

1. Hoult, J.R.S.; Paya, M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen. Pharmacol., 1996, 27, 713-722.
2. Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr. Med. Chem., 2005, 12, 887- 916.
3. Anand, P.; Singh, B.; Singh N. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease. Bioorg. Med. Chem., 2012, 20, 1175-1180.
4. Wu, L.; Wang, X.; Xu, W.; Farzaneh, F.; Xu, R. The structure and pharmacological functions of coumarins and their derivatives. Curr. Med. Chem., 2009, 16, 4236-4260.
5. Stahmann, M.A.; Huebner, C.F., Link, K.P. Studies on haemorrhagic sweet clover disease V: identification and synthesis of the haemorrhagic agent. J. Biol. Chem., 1941, 138, 513-527.
6. Lacy, A.; O'Kennedy, R. Studies on coumarins and coumarinrelated compounds to determine their therapeutic role in the treatment of cancer. Curr. Pharm. Des., 2004, 10, 3797-3811.
7. Orhan, G.; Orhan, I.; Subutay-Oztekin, N.; Ak, F.; Sener, B. Contemporary anticholinesterase pharmaceuticals of natural origin and their synthetic analogues for the treatment of Alzheimer's disease. Rec. Pat. CNS Drug Disc., 2009, 4, 43-51.
8. Terry, A.V.; Buccafusco, J.J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther., 2003, 306, 821-827.
9. Orhan, I.E., Orhan, G., Gurkas, E. An overview on natural cholinesterase inhibitors - A multi-targeted drug class - and their mass production. Mini Rev. Med. Chem., 2011, 11, 836-842.
10. de Aquino, R.A.N., Modolo, L.V., Alves, R.B., de Fatima, A. Design of new drugs for the treatment of Alzheimer's disease based on tacrine structure. Curr. Drug Targets, 2013, 14, 378-397.
11. Fujioka, T. Myasthenia gravis and acetylcholine. Brain & Nerve, 2014, 66, 517-525.
12. De Los Rios, C. Cholinesterase inhibitors: A patent review (2007 - 2011). Exp. Opin. Therapeutic Patents, 2012, 22, 853-869.
13. Song, M.S., Matveychuk, D., MacKenzie, E.M., Duchcherer, M., Mousseau, D.D., Baker, B. An update on amine oxidase inhibitors: Multifaceted drugs. Progr. Neuro-Psychopharmacol. Biol. Psychiatry, 2013, 44, 118-124.
14. Ono, K., Hasegawa, K., Naiki, H., Yamada, M. Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta amyloids fibrils in vitro. Neurochem. Int., 2006, 48, 275, 285.
15. Bautista-Aguilera, O.M., Esteban, G., Chioua, M., Nikolic, K., Agbaba, D., Moraleda, I., Iriepa, I., Soriano, E., Samadi, A., Unzeta, M., Marco-Contelles, J. Multipotent cholinesterase/ monoamine oxidase inhibitors for the treatment of Alzheimer's disease: Design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids. Drug Des. Dev. Ther., 2014, 8, 1893-1910.
16. Kumar, A., Jain, S., Parle, M., Jain, N., Kumar, P. 3-Aryl-1-phenyl- 1H-pyrazole derivatives as new multitarget directed ligands for the treatment of Alzheimer's disease, with acetylcholinesterase and monoamine oxidase inhibitory properties. Excli. J., 2013, 12, 1030- 1042.
17. Yanez, M., Vina, D. Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease. Curr. Topics Med. Chem., 2013, 13, 1692-1706.
18. Grossmann, V.; Hais, I.M.; Kasalicky, B. Inhibition of human serum cholinesterase by some 4-hydroxy-coumarin derivatives. Nature, 1950, 165, 276.
19. Janok, J.; Majerova, Z.; Valentinova, I.; Masek, J.; Tichy, V. In vitro anticholinesterase effect of coumarin dialkylphosphoric & dialkylthiophosphoric acid esters. Prac Lek., 1957, 9, 506-512.
20. Simeon-Rudolf, V.; Kovarik, Z, Radić, Z.; Reiner, E. Reversible inhibition of acetylcholinesterase and butyrylcholinesterase by 4,4'- bipyridine and by a coumarin derivative. Chem. Biol. Interact., 1999, 119-120, 119-128.
21. Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartolini, M.; Andrisano,V.; Valenti,P.; Recanatini,M. 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2- chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase- induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J. Med. Chem., 2003, 46, 2279-2282.
22. Bruhlmann, C.; Ooms, F.; Carrupt, P. A.; Testa, B.; Catto, M.; Leonetti, F.; Altomare, C.; Carotti, A. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J. Med. Chem., 2001, 44, 3195-3198.
23. Shen, Q.; Peng, Q.; Shao, J.; Liu, X.; Huang, Z.; Pu, X.; Ma, L.; Li, Y. M.; Chan, A. S.; Gu, L. Synthesis and biological evaluation of functionalized coumarins as acetylcholinesterase inhibitors. Eur. J. Med. Chem., 2005, 40, 1307-1315.
24. Leonetti, F.; Catto, M.; Nicolotti, O.; Pisani, L.; Cappa, A.; Stefanachi, A.; Carotti, A. Homo- and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors. Bioorg. Med. Chem., 2008, 16, 7450-7456.
25. Zhou, X.; Wang, X.B.; Wang, T.; Kong, L.Y. Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg. Med. Chem., 2008, 16, 8011-8021.
26. Sourgens, H.; Hoerr, R.; Biber, A.; Steinbrede, H.; Derendorf, H. KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers. J. Clin. Pharmacol., 1998, 38, 373-381.
27. Hilgert, M.; Noldner, M.; Chatterjee, S.S.; Klein, J. KA-672 inhibits rat brain acetylcholinesterase in vitro but not in vivo. Neurosci. Lett., 1999, 263, 193-196.
28. Reisner, E.; Noldner, M.; Rossner, S.; Chatterjee, S.S.; Bigl, V.; Schliebs, R. Acute effect of KA-672, a putative cognitive enhancer, on neurotransmitter receptor binding in mouse brain. Neurosci. Lett., 1999, 274, 187-190.
29. Hoerr, R.; Noeldner, M. Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment. CNS Drug Rev., 2002, 8, 143-158.
30. Kang, S.Y.; Lee, K.Y.; Sung, S.H.; Park, M.J.; Kim, Y.C. Coumarins isolated from Angelica gigas inhibit acetylcholinesterase: structure- activity relationships. J. Nat. Prod., 2001, 64, 683-685.
31. Kang, S.Y.; Lee, K.Y.; Park, M.J.; Kim, Y.C.; Markelonis, G.T.; Oh, T.H.; Kim, Y.C. Decursin from Angelica gigas mitigates amnesia induced by scopolamine in mice. Neurobiol. Learn. Memory, 2003, 79, 11-18.
32. Kim, D.H.; Kim, D.Y.; Kim, Y.C.; Jung, J.W.; Lee, S.; Yoon, B.H.; Cheong, J.H.; Kim, Y.S.; Kang, S.S., Ko, K.H.; Ryu, J.H. Nodakenin, a coumarin compound, ameliorates scopolamine-induced memory disruption in mice. Life Sci., 2007, 80, 1944-1950.
33. Seo, W.D.; Kim, J.Y.; Ryu, H.W.; Kim, J.H.; Han, S.I.; Ra, J.E.; Seo, K.H.; Jang, K.C.; Lee, J.H. Identification and characterisation of coumarins from the roots of Angelica dahurica and their inhibitory effects against cholinesterase. J. Funct. Foods, 2013, 5, 1421- 1431.
34. Senol, F.S.; Skalicka Wozniak, K.; Khan, M.T.H.; Orhan, I.E.; Sener, B.; Glowniak, K. An in vitro and in silico approach to cholinesterase inhibitory and antioxidant effects of the methanol ex tract, furanocoumarin fraction, and major coumarins of Angelica officinalis L. fruits. Phytochem. Lett., 2011, 4, 462-467.
35. Orhan, I.; Tosun, F.; Sener, B. Coumarin, anthroquinone and stilbene derivatives with anticholinesterase activity. Z. Naturforsch. Sect. C, 2008, 63, 366-370.
36. Kumar, P.; Singh, V.K.; Singh, D.K. Kinetics of enzyme inhibition by active molluscicidal agents ferulic acid, umbelliferone, eugenol and limonene in the nervous tissue of snail. Lymnaea acuminata. Phytother. Res., 2009, 23, 172-177.
37. Ben Salem, S.; Jabrane, A.; Harzallah-Skhiri, F.; Ben Jannet, H. New bioactive dihydrofuranocoumarins from the roots of the Tunisian Ferula lutea (Poir.) Maire. Bioorg. Med. Chem. Lett., 2013, 23, 4248-4252.
38. Miyazawa, M.; Tsukamoto, T.; Anzai, J.; Ishikawa, Y. Insecticidal effect of phthalides and furanocoumarins from Angelica acutiloba against Drosophila melanogaster. J. Agric. Food Chem., 2004, 52, 4401-445.
39. Sigurdsson, S.; Gudbjarnason, S. Inhibition of acetylcholinesterase by extracts and constituents from Angelica archangelica and Geranium sylvaticum. Z. Naturforsch., 2007, 62, 689-693.
40. Wszelaki, N.; Paradowska, K.; Jamroz, M.K.; Granica, S.; Kiss, A.K. Bioactivity-guided fractionation for the butyrylcholinesterase inhibitory activity of furanocoumarins from Angelica archangelica L. roots and fruits. J. Agric. Food Chem., 2011, 59, 9186-9193.
41. Urbain, A.; Marston, A.; Hostettman, K. Coumarins from Peucedanum ostruthium as inhibitors of acetylcholinesterase. Pharm. Biol., 2005, 43, 647-650.
42. Choudhary, M.I.; Azizuddin, Khalid, A.; Sultani, S.Z.; Atta-ur- Rahman. A new coumarin from Murraya paniculata. Planta Med., 2002, 68, 81-83.
43. Saied, S.; Nizami, S.S.; Anis, I. Two new coumarins from Murraya paniculata. J. Asian Nat. Prod. Res., 2008, 10, 515-519.
44. Lee, J.H.; Lee, K.T.; Yang, J.H.; Baek, N.I.; Kim, D.K. Acetylcholinesterase inhibitors from the twigs of Vaccinium oldhami Miquel. Arch. Pharm. Res., 2004, 27, 53-56.
45. Rollinger, J.M.; Hornick, A.; Langer, T.; Stuppner, H.; Prast, H. Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products. J. Med. Chem., 2004, 47, 6248-6254.
46. Yun, B.S.; Lee, I.K.; Ryoo, I.J.; Yoo, I.D. Coumarins with monoamine oxidase inhibitory activity and antioxidative coumarinolignans from Hibiscus syriacus. J. Nat. Prod., 2001, 64, 1238- 1240.
47. Dall'Acqua, S.; Maggi, F.; Minesso, P.; Salvagno, M.; Papa, F.; Vittori, S.; Innocenti, G. Identification of non-alkaloid acetylcholinesterase inhibitors from Ferulago campestris (Besser) Grecescu (Apiaceae). Fitoterapia, 2010, 81, 1208-1212.
48. Awang, K.; Chan, G.; Litaudon, M.; Ismail, N.H.; Martin, M.T.; Gueritte, F. 4-Phenylcoumarins from Mesua elegans with acetylcholinesterase inhibitory activity. Bioorg. Med. Chem., 2010, 18, 7873-7877.
49. Changwong, N.; Sabphon, C.; Ingkaninan, K.; Sawasdee, P. Acetyl- and butyryl-cholinesterase inhibitory activities of mansorins and mansonones. Phytother. Res., 2012, 26, 392-396.
50. Kim, J.K.; Choi, S.J.; Bae, H.; Kim, C.R.; Cho, H.Y.; Kim, Y.J.; Lim, S.T.; Kim, C.J.; Kim, H.K.; Peterson, S.; Shin, D.H. Effects of methoxsalen from Poncirus trifoliata on acetylcholinesterase and trimethyltin-induced learning and memory impairment. Biosci. Biotechnol. Biochem., 2011, 75, 1984-1989.
51. Fallarero, A.; Oinonen, P.; Gupta, S.; Blom, P.; Galkin, A.; Mohan, C.G.; Vuorela, P.M. Inhibition of acetylcholinesterase by coumarins: the case of coumarin 106. Pharmacol. Res., 2008, 58, 215-221.
52. Di Giovanni, S,; Borloz, A.; Urbain, A.; Marston, A.; Hostettmann, K.; Carrupt, P.A.; Reist, M. In vitro screening assays to identify natural or synthetic acetylcholinesterase inhibitors: thin layer chromatography versus microplate methods. Eur. J. Pharm. Sci., 2008, 33, 109-119.
53. Phoopichayanun, C.; Phuwapraisirisan, P.; Tip-Pyang, S.; Jongaramruong, J. Complete NMR assignment and absolute configuration of feronielloside, a new acetylcholinesterase inhibitor from Feroniella lucida. Nat. Prod. Res., 2008, 22, 1297-1303.
54. Youkwan, J.; Sutthivaiyakit, S.; Sutthivaiyakit, P. Citrusosides A-D and furanocoumarins with cholinesterase inhibitory activity from the fruit peels of Citrus hystrix. J. Nat. Prod., 2010, 73, 1879-1883.
55. Alipour, M.; Khoobi, M.; Foroumadi, A.; Nadri, H.; Moradi, A.; Sakhteman, A.; Ghandi, M.; Shafiee, A. Novel coumarin derivatives bearing N-benzyl pyridinium moiety: potent and dual binding site acetylcholinesterase inhibitors. Bioorg. Med. Chem., 2012, 20, 7214-7222.
56. Catto, M.; Pisani, L.; Leonetti, F.; Nicolotti, O.; Pesce, P.; Stefanachi, A.; Cellamare, S.; Carotti, A. Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. Bioorg. Med. Chem., 2013, 21, 146-152.
57. Alipour, M.; Khoobi, M.; Nadri, H.; Sakhteman, A.; Moradi, A.; Ghandi, M.; Foroumadi, A.; Shafiee, A. Synthesis of some new 3- coumaranone and coumarin derivatives as dual inhibitors of acetyland butyrylcholinesterase. Arch. Pharm. (Weinheim), 2013, 346, 577-587.
58. Bag, S.; Ghosh, S.; Tulsan, R.; Sood, A.; Zhou, W.; Schifone, C.; Foster, M.; Le Vine, H3rd.; Torok, B.; Torok, M. Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer's disease. Bioorg. Med. Chem. Lett., 2013, 23, 2614-2618.
59. Razavi, S.F.; Khoobi, M.; Nadri, H.; Sakhteman, A., Moradi, A.; Emami, S.; Foroumadi, A.; Shafiee, A. Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors. Eur. J. Med. Chem., 2013, 64, 252-259.
60. Alipour, M.; Khoobi, M.; Moradi, A.; Nadri, H.; Homayouni Moghadam, F.; Emami, S.; Hasanpour, Z.; Foroumadi, A.; Shafiee, A. Synthesis and anti-cholinesterase activity of new 7- hydroxycoumarin derivatives. Eur. J. Med. Chem., 2014, 82, 536- 544.
61. Anand, P.; Singh, B. A review on cholinesterase inhibitors for Alzheimer's disease. Arch. Pharm. Res., 2013, 36, 375-399.
62. Wilkinson, D.G.; Francis, P.T.; Schwam, E.; Payne-Parrish, J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging, 2004, 21, 453-478.
63. Francis, P.T.; Palmer, A.M.; Snape, M.; Wilcock, G.K. The cholinergic hypothesis of Alzheimer's Disease: A review of progress. J. Neurol. Neurosurg. Psych., 1999, 66,137-147.
64. Schliebs, R. Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem. Res., 2005, 30, 895-908.
65. Mann, D.M.; Yates, P.O. Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders. Hum. Neurobiol., 1986, 5,147-158.
66. Huey, E.D.; Putnam, K.T.; Grafman, J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology, 2006, 10,17-22.
67. Weinreb, O.; Mandel, S.; Bar-Am, O.; Yogev, M.; Avramovich, T.Y.; Amit, T.; Youdim, M.B. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics, 2009, 6,163-174.
68. Filip, V.; Kolibas, E. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J. Psych. Neurosci., 1999, 24, 234-243.
69. Youdim, M.B.; Edmondson, D.; Tipton, K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci., 2006, 7, 295-309.
70. Shih, J.C.; Chen, K. Regulation of MAO-A and MAO-B gene expression. Curr. Med. Chem., 2004, 11, 1995-2005.
71. Kalgutkar, A.S.; Dalvie, D.K.; Castagnoli, N.; Taylor, T.J. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol., 2001, 14, 1139-62.
72. Meyer, J.H.; Ginovart, N.; Boovariwala, A.; Sagrati, S.; Hussey, D.; Garcia, A.; Young, T.; Praschak-Rieder, N.; Wilson, A.A.; Houle, S. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry, 2006, 63, 1209-1216.
73. Du, L.; Bakish, D.; Ravindran, A.; Hrdina, P.D. MAOA gene polymorphisms are associated with major depression and sleep disturbance in males. NeuroRep., 2004, 15, 2097-2101.
74. Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson, D.E.; Mattevi, A. Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J. Med. Chem., 2004, 47, 1767-1774.
75. Saura, J.; Luque, J.M.; Cesura, A.M.; Da Prada, M.; Chan-Palay, V.; Huber, G.; Löffler, J.; Richards, J.G. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neurosci., 1994, 62, 15-30.
76. Youdim, M.B.; Buccafusco, J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci., 2005, 26, 27-35.
77. Jerris, P.; Smith, A.B. Synthesis and configurational assignment of geiparvarin. A novel antitumor agent. J. Org. Chem., 1981, 46, 577-585.
78. Carotti, A.; Carrieri, A.; Chimichi, S.; Boccalini, M.; Cosimelli B.; Gnerre, C.; Carotti, A.; Carrupt, P.A.; Testa, B. Natural and synthetic geiparvarins are strong and selective MAO-B inhibitors. Synthesis and SAR studies. Bioorg. Med. Chem. Lett., 2002, 16, 3551- 3355.
79. Hossain, C.F.; Okuyama, E.; Yamazaki, M. A new series of coumarin derivatives having monoamineoxidase inhibitory activity from Monascus anka. Chem. Pharm. Bull., 1996, 44, 1535-1539.
80. Yun, B.S.; Lee, I.K.; Ryoo, I.J.; Yoo, I.D. Coumarins with monoamine oxidase inhibitory activity and antioxidative coumarinolignans from Hibiscus syriacus. J. Nat. Prod., 2001, 64, 1238-1240.
81. Huong, D.T.; Choi, H.C.; Rho, T.C.; Lee, H.S.; Lee, M.K.; Kim, Y.H. Inhibitory activity of monoamine oxidase by coumarins from Peucedanum japonicum. Arch. Pharm. Res., 1999, 22, 324-326.
82. Jeong, S.H.; Han, X.H.; Hong, S.S.; Hwang, J.S.; Hwang, J.H.; Lee, D.; Lee, M.K.; Ro, J.S.; Hwang, B.Y. Monoamine oxidase inhibitory coumarins from the aerial parts of Dictamnus albus. Arch. Pharm. Res., 2006, 29, 1119-1124.
83. Jo, Y.S.; Huong, D.T.; Bae, K.; Lee, M.K.; Kim, Y.H. Monoamine oxidase inhibitory coumarin from Zanthoxylum schinifolium. Planta Med., 2002, 68, 84-85.
84. Matos, M.J.; Viña, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.; Uriarte, E. A new series of 3- phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 3268-70.
85. Matos, M.J.; Viña, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 5053-5055.
86. Matos, M.J.; Viña, D.; Janeiro, P.; Borges, F.; Santana, L.; Uriarte, E. New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 5157- 5160.
87. Matos, M.J.; Terán, C.; Pérez-Castillo, Y.; Uriarte, E.; Santana, L.; Viña, D. Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. J. Med. Chem., 2011, 54, 7127-7137.
88. Matos, M.J.; Vilar, S.; García-Morales, V.; Tatonetti N.P.; Uriarte, E.; Santana, L.; Viña, D. Insight into the functional and structural properties of 3-arylcoumarin as an interesting scaffold in monoamine oxidase B inhibition. ChemMedChem., 2014, 9, 1488-1500.
89. Matos, M.J.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L.; Viña, D. MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins. Bioorg. Med. Chem. Lett., 2011, 21, 4224- 4227.
90. Viña, D.; Matos, M.J.; Ferino, G.; Cadoni, E.; Laguna, R.; Borges, F.; Uriarte, E.; Santana, L. 8-Substituted 3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation, and docking studies. ChemMedChem., 2012, 7, 464- 470.
91. Dolores, V.; Matos, M.J.; Yanez, M.; Santana, L.; Uriarte, E. 3- Substituted coumarins as dual inhibitors of AChE and MAO for the treatment of Alzheimer's disease. Med. Chem. Comm., 2012, 3, 213-218.
92. Serra, S.; Ferino, G.; Matos, M.J.; Vázquez-Rodríguez, S.; Delogu, G.; Viña, D.; Cadoni, E.; Santana, L.; Uriarte, E. Hydroxycoumarins as selective MAO-B inhibitors. Bioorg. Med. Chem Lett., 2012, 22, 258-261.
93. Delogu, G.; Picciau, C.; Ferino, G.; Quezada, E.; Podda, G.; Uriarte, E.; Viña, D. Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3- heteroarylcoumarin derivatives. Eur. J. Med. Chem., 2011, 46, 1147-1152.
94. Rendenbach, M.B.; Schlecker, R.; Traut, M.; Weifenbachs, H. Synthesis of coumarins as subtype inhibitors of monoamine oxidase. Bioorg. Med. Chem. Lett., 1994, 4, 1195-1198.
95. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J. Med. Chem., 2000, 43, 4747- 4758.
96. Pisani, L.; Muncipinto, G.; Miscioscia, T.F.; Nicolotti, O.; Leonetti, F.; Catto, M.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez- Alvarez, E.; Passeleu, C.; Carotti, A. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor. J. Med. Chem., 2009, 52, 6685-6706.
97. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.; Carradori, S.; Yáñez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7- substituted coumarins. J. Med. Chem., 2009, 52, 1935-1942.
98. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F. Inhibition of monoamine oxidases by coumarin-3-acyl derivatives: biological activity and computational study. Bioorg. Med. Chem. Lett., 2004, 14, 3697-3703.
99. Secci, D.; Carradori, S.; Bolasco, A.; Chimenti, P.; Yáñez, M.; Ortuso, F.; Alcaro, S. Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives. Eur. J. Med. Chem., 2011, 46, 4846-4852.
100. Lopez-Castello, N.; Rodriguez, A.; Porta, B.; Gomez, M. Process for the obtention of coumaric acid from coumarin. Analysis of the reaction conditions. Adv. Chem. Eng. Sci., 2013, 3, 195-201.
101. Ewais, H.; Asiri, A.; Ismail, I.; Hameed, S.; Abdel-Khalek, A. Kinetics and the mechanism of the ring opening of 3- carboethoxycoumarin by sodium ethoxide and hydraizne. Res. J. Chem. Sci., 2012, 2, 57-64.
102. Mao, B.; Mastral, M.; Feringa, B. Asymmetric conjugate addition of Grignard reagents to pyrannones. Org. Lett., 2013, 15, 286-289.
103. Gallagher, B.; Taft, B.; Lipshutz, B. Asymmetric conjugate reduction of coumarins. A new route to tolterodine and related coumarin derivatives. of Grignard reagents to pyrannones. Org. Lett., 2009, 11, 5374-5377.
104. Girotti, R.; Marrocchi, A.; Minuti, L.; Piermatti, O.; Pizzo, F.; Vaccaro, L. Diels Alder reactions of 3-substituted coumarins in water and high pressure condition. An uncatalyzed route to tetrahydro- 6H-benzo[c]chrome-6-ones. J. Org. Chem., 2006, 71, 70-74.
105. Zhou, X.; Zhao, W.; Zheng, J.; Humphreys, W.; Shu, Y.; Zhu, M. Bioactivation of coumarin in rat olfactory mucosal microsomes. Detection of protein covalent binding and identification of reactive intermediates through analysis of glutathione adducts. Chem-Biol. Interact., 2009, 181, 227-235.
106. Lacy, A.; O'Kennedy, R. Studies on coumarins and coumarinrelated compounds to determine their therapeutic role in the treatment of cancer. Curr. Phar. Des., 2004, 10, 3797-3811.
107. Holford, N.H. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin. Pharmacokin., 1986, 11, 483-504.
108. Brühlmann, C.; Ooms, F.; Carrupt, P.A.; Testa, B.; Catto, M.; Leonetti, F.; Altomare, C.; Carotti, A. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J. Med. Chem., 2001, 44, 3195-3198.